A prospective, active control, open-label, multi-centre, randomized clinical trial comparing BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System vs. Xience family of Everolimus Eluting Coronary Stent System to evaluate safety and performance in patients with de novo coronary bifurcation lesions. - BioMime Branch - Sirolimus Eluting Coronary Side Branch Stent System
Latest Information Update: 04 Jul 2019
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors Meril Life Sciences
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.
- 02 Jan 2018 New trial record